(2R)-2-(3-氨基丙基)-5-(2,5-二氟苯基)-N-甲氧基-N-甲基-2-苯基-1,3,4-噻二唑-3(2H)-甲酰胺 | 885060-08-2

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2R)-2-(3-氨基丙基)-5-(2,5-二氟苯基)-N-甲氧基-N-甲基-2-苯基-1,3,4-噻二唑-3(2H)-甲酰胺
• 英文名称: (R)-Filanesib
• 英文别名: (2R)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide
• CAS: 885060-08-2
• 化学式: C₂₀H₂₂F₂N₄O₂S
• 分子量: 420.5
• InChiKey: LLXISKGBWFTGEI-HXUWFJFHSA-N

物化性质

• 沸点：
  511.3±60.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  96.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• INHIBITORS OF MITOSIS FOR INCREASING APOPTOSIS IN THERAPY
  申请人：Array Biopharma, Inc.

  公开号：EP2349259B1

  公开（公告）日：2015-12-23
• MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION
  申请人：Cytokinetics, Inc.

  公开号：EP2582682B1

  公开（公告）日：2015-01-14
• METHODS OF TREATING LUNG DISEASE
  申请人：Cytokinetics, Inc.

  公开号：EP2582682A1

  公开（公告）日：2013-04-24
• Method of Treatment Using Inhibitors of Mitosis
  申请人：Tunquist Brian J.

  公开号：US20100099697A1

  公开（公告）日：2010-04-22

  Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.
• METHOD OF TREATMENT USING INHIBITORS OF MITOSIS
  申请人：Array BioPharma Inc.

  公开号：US20170172988A1

  公开（公告）日：2017-06-22

  Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.